Cargando…

Ovarian cancer immunotherapy: opportunities, progresses and challenges

Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bei, Nash, John, Runowicz, Carolyn, Swede, Helen, Stevens, Richard, Li, Zihai
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831814/
https://www.ncbi.nlm.nih.gov/pubmed/20146807
http://dx.doi.org/10.1186/1756-8722-3-7
_version_ 1782178270256562176
author Liu, Bei
Nash, John
Runowicz, Carolyn
Swede, Helen
Stevens, Richard
Li, Zihai
author_facet Liu, Bei
Nash, John
Runowicz, Carolyn
Swede, Helen
Stevens, Richard
Li, Zihai
author_sort Liu, Bei
collection PubMed
description Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.
format Text
id pubmed-2831814
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28318142010-03-04 Ovarian cancer immunotherapy: opportunities, progresses and challenges Liu, Bei Nash, John Runowicz, Carolyn Swede, Helen Stevens, Richard Li, Zihai J Hematol Oncol Review Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer. BioMed Central 2010-02-10 /pmc/articles/PMC2831814/ /pubmed/20146807 http://dx.doi.org/10.1186/1756-8722-3-7 Text en Copyright ©2010 PLiu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Liu, Bei
Nash, John
Runowicz, Carolyn
Swede, Helen
Stevens, Richard
Li, Zihai
Ovarian cancer immunotherapy: opportunities, progresses and challenges
title Ovarian cancer immunotherapy: opportunities, progresses and challenges
title_full Ovarian cancer immunotherapy: opportunities, progresses and challenges
title_fullStr Ovarian cancer immunotherapy: opportunities, progresses and challenges
title_full_unstemmed Ovarian cancer immunotherapy: opportunities, progresses and challenges
title_short Ovarian cancer immunotherapy: opportunities, progresses and challenges
title_sort ovarian cancer immunotherapy: opportunities, progresses and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831814/
https://www.ncbi.nlm.nih.gov/pubmed/20146807
http://dx.doi.org/10.1186/1756-8722-3-7
work_keys_str_mv AT liubei ovariancancerimmunotherapyopportunitiesprogressesandchallenges
AT nashjohn ovariancancerimmunotherapyopportunitiesprogressesandchallenges
AT runowiczcarolyn ovariancancerimmunotherapyopportunitiesprogressesandchallenges
AT swedehelen ovariancancerimmunotherapyopportunitiesprogressesandchallenges
AT stevensrichard ovariancancerimmunotherapyopportunitiesprogressesandchallenges
AT lizihai ovariancancerimmunotherapyopportunitiesprogressesandchallenges